AI Article Synopsis
- Rats were trained to distinguish Delta9-tetrahydrocannabinol (THC) from other drugs like morphine and PCP, showing a rapid acquisition of this discrimination in 38 days.
- In tests, high doses of anandamide partially substituted for THC, while its more stable analog (R)-methanandamide fully substituted for THC in the control group, indicating varying degrees of similarity in effects.
- The Delta9-THC-other procedure was found to produce a more selective response compared to typical drug-no drug training, as most drugs had lower substitution rates in the THC-other group.
Article Abstract
In an attempt to increase the selectivity of the discriminative stimulus effects of Delta9-tetrahydrocannabinol (THC), rats were trained to discriminate 3.2 mg/kg of this compound from a group of "other" drugs consisting of morphine (3.2 mg/kg), PCP (2.5 mg/kg), and vehicle. Acquisition of the Delta9-THC-other discrimination was rapid (38 days) and did not differ significantly from that of a group of "control" animals trained to discriminate Delta9-THC (3.2 mg/kg) from its vehicle (33 days). In substitution (generalization) tests, a high dose of anandamide, which also severely decreased response rate, substituted partially in both the control and the Delta9-THC-other group; (R)-methanandamide, an analog of anandamide which is metabolized more slowly, substituted completely for Delta9-THC in the control, and partially in the Delta9-THC-other group; neither pentobarbital nor diazepam substituted completely for Delta9-THC under any experimental condition. Regardless of the level of Delta9-THC lever responding, all drugs except diazepam substituted less in the Delta9-THC-other than in the control group. For this reason, the Delta9-THC-other training procedure might be described as being more selective than the commonly used drug-no drug procedure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pbb.2004.08.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Major Adverse Kidney Events in Hospitalized Older Patients With Acute Kidney Injury: Machine Learning-Based Model Development and Validation Study.
J Med Internet Res
January 2025
Department of Nephrology, Hunan Key Laboratory of Kidney Disease and Blood Purification, The Second Xiangya Hospital of Central South University, Changsha, China.
Background: Acute kidney injury (AKI) is a common complication in hospitalized older patients, associated with increased morbidity, mortality, and health care costs. Major adverse kidney events within 30 days (MAKE30), a composite of death, new renal replacement therapy, or persistent renal dysfunction, has been recommended as a patient-centered endpoint for clinical trials involving AKI.
Objective: This study aimed to develop and validate a machine learning-based model to predict MAKE30 in hospitalized older patients with AKI.
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
Robarts Research Institute, London, ON, Canada.
Background: ApoE4 is the strongest genetic risk factor for late onset Alzheimer's Disease (AD). However, ApoE4 has also been suggested to exhibit antagonistic pleiotropy, a phenomenon by which some allelic variations of a gene promote fitness during certain periods of life but may be detrimental in others. Previous work suggests that ApoE4 carriers exhibit superior performance on executive function tasks in early and middle age, while later in life (>70 years) ApoE4 carriers experience greater cognitive decline across multiple domains.
View Article and Find Full Text PDFBasic Science and Pathogenesis.
Alzheimers Dement
December 2024
Johns Hopkins University, Baltimore, MD, USA.
Background: Alzheimer's disease is a progressive form of dementia where cognitive capacities deteriorate due to neurodegeneration. Interestingly, Alzheimer's patients exhibit cognitive fluctuations during all stages of the disease. Though it is thought that contextual factors are critical for unlocking these hidden memories, understanding the neural basis of cognitive fluctuations has been hampered due to the lack of behavioral approaches to dissociate memories from contextual-performance.
View Article and Find Full Text PDFBackground: There is currently an unmet need for novel accessible biomarkers that capture the complex and heterogenous pathophysiology of Alzheimer's disease (AD). Over the past decade, the systems-based multi-omic approaches employed by the Accelerating Medicines Partnership in AD (AMP-AD) have resulted in the identification of promising peripheral markers of disease heterogeneity. This scientific review will highlight these advances with a particular focus on the consortium's successes in peripheral protein biomarker discovery in cerebrospinal fluid (CSF) and plasma.
View Article and Find Full Text PDFBasic Science and Pathogenesis.
Alzheimers Dement
December 2024
Neuroscience Institute, NYU Langone Health, NYU Grossman School of Medicine, New York, NY, USA.
Background: The entorhinal cortex and hippocampus are loci of early vulnerability in AD. These areas are crucial for episodic memory processing for space and contexts. The majority of AD model mouse imaging and electrode studies utilize simple tasks such open field and linear track.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!